FDA Determines Regulatory Review Period for WINREVAIR Patent Extension

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for WINREVAIR, a human biological product, following patent extension applications submitted to the US Patent and Trademark Office (USPTO).